Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center, Randomized, Double-blinded, Placebo-controlled, Multiple-ascending-dose Study of Brentuximab Vedotin in Adults With Active Systemic Lupus Erythematosus

NCT02533570 is registered in ClinicalTrials.gov with Seagen Inc. as lead sponsor.

NCT NCT02533570
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02533570 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center, Randomized, Double-blinded, Placebo-controlled, Multiple-ascending-dose Study of Brentuximab Vedotin in Adults With Active Systemic Lupus Erythematosus
Lead sponsor
Seagen Inc.
Phase
Phase 2
Overall status
Terminated
Start date
July 31, 2015
Completion date
June 5, 2017
Enrollment
20 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

systemic lupus erythematosus